Valbenazine for the Treatment of Adults with Tardive Dyskinesia
# Purpose of review This a comprehensive review of the literature regarding the use of Valbenazine in treating tardive dyskinesia. A primarily oral movement disorder induced by chronic exposure to certain classes of medications, tardive dyskinesia is often resistant to many therapeutic approaches....
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Medical Publishing
2021-06-01
|
| Series: | Health Psychology Research |
| Online Access: | https://doi.org/10.52965/001c.24929 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823857476111433728 |
|---|---|
| author | Harshit Gupta Alycee R. Moity Allison Jumonville Sarah Kaufman Amber N. Edinoff Alan D. Kaye |
| author_facet | Harshit Gupta Alycee R. Moity Allison Jumonville Sarah Kaufman Amber N. Edinoff Alan D. Kaye |
| author_sort | Harshit Gupta |
| collection | DOAJ |
| description | # Purpose of review
This a comprehensive review of the literature regarding the use of Valbenazine in treating tardive dyskinesia. A primarily oral movement disorder induced by chronic exposure to certain classes of medications, tardive dyskinesia is often resistant to many therapeutic approaches. This review presents the background, evidence, and indications for the use of Valbenazine as a treatment option for this condition.
# Recent Findings
Tardive dyskinesia is a disorder arising from long-term exposure to medications that blocked dopamine receptors, primarily antipsychotics. It is characterized by abnormal movements of the oral-buccal-lingual structures as well as associated pain and hypertrophy. Simply stopping the use of the dopamine blocking agents effectively alleviates the symptoms but is not always reliable hence the need for another therapeutic approach.
Valbenazine is thought to function as a highly selective inhibitor of the VMAT2 vesicular monoamine transporter resulting in decreased availability of dopamine in the presynaptic cleft. This leads to decreased dopaminergic activation of the striatal motor pathway. The FDA approved Valbenazine in 2017 to treat tardive dyskinesia in adults and needs to be evaluated with existing therapeutic approaches.
# Summary
The chronic use of dopamine receptor blocking agents, most commonly antipsychotics, can lead to a movement disorder called tardive dyskinesia. Once symptom onset has occurred, these movement abnormalities can persist for years to permanently, depending on the speed and effectiveness of treatment. Valbenazine is a relatively newer option for the treatment of tardive dyskinesia in adults. Compared to other pharmaceutical agents, it is more selective and has limited toxicities making it an effective treatment regimen. However, further research, including additional direct comparison studies, should be conducted to fully evaluate this drug’s usefulness. |
| format | Article |
| id | doaj-art-1a92e4d50e22478c8ad0d05b7d8a16d1 |
| institution | Kabale University |
| issn | 2420-8124 |
| language | English |
| publishDate | 2021-06-01 |
| publisher | Open Medical Publishing |
| record_format | Article |
| series | Health Psychology Research |
| spelling | doaj-art-1a92e4d50e22478c8ad0d05b7d8a16d12025-02-11T20:30:41ZengOpen Medical PublishingHealth Psychology Research2420-81242021-06-0191Valbenazine for the Treatment of Adults with Tardive DyskinesiaHarshit GuptaAlycee R. MoityAllison JumonvilleSarah KaufmanAmber N. EdinoffAlan D. Kaye# Purpose of review This a comprehensive review of the literature regarding the use of Valbenazine in treating tardive dyskinesia. A primarily oral movement disorder induced by chronic exposure to certain classes of medications, tardive dyskinesia is often resistant to many therapeutic approaches. This review presents the background, evidence, and indications for the use of Valbenazine as a treatment option for this condition. # Recent Findings Tardive dyskinesia is a disorder arising from long-term exposure to medications that blocked dopamine receptors, primarily antipsychotics. It is characterized by abnormal movements of the oral-buccal-lingual structures as well as associated pain and hypertrophy. Simply stopping the use of the dopamine blocking agents effectively alleviates the symptoms but is not always reliable hence the need for another therapeutic approach. Valbenazine is thought to function as a highly selective inhibitor of the VMAT2 vesicular monoamine transporter resulting in decreased availability of dopamine in the presynaptic cleft. This leads to decreased dopaminergic activation of the striatal motor pathway. The FDA approved Valbenazine in 2017 to treat tardive dyskinesia in adults and needs to be evaluated with existing therapeutic approaches. # Summary The chronic use of dopamine receptor blocking agents, most commonly antipsychotics, can lead to a movement disorder called tardive dyskinesia. Once symptom onset has occurred, these movement abnormalities can persist for years to permanently, depending on the speed and effectiveness of treatment. Valbenazine is a relatively newer option for the treatment of tardive dyskinesia in adults. Compared to other pharmaceutical agents, it is more selective and has limited toxicities making it an effective treatment regimen. However, further research, including additional direct comparison studies, should be conducted to fully evaluate this drug’s usefulness.https://doi.org/10.52965/001c.24929 |
| spellingShingle | Harshit Gupta Alycee R. Moity Allison Jumonville Sarah Kaufman Amber N. Edinoff Alan D. Kaye Valbenazine for the Treatment of Adults with Tardive Dyskinesia Health Psychology Research |
| title | Valbenazine for the Treatment of Adults with Tardive Dyskinesia |
| title_full | Valbenazine for the Treatment of Adults with Tardive Dyskinesia |
| title_fullStr | Valbenazine for the Treatment of Adults with Tardive Dyskinesia |
| title_full_unstemmed | Valbenazine for the Treatment of Adults with Tardive Dyskinesia |
| title_short | Valbenazine for the Treatment of Adults with Tardive Dyskinesia |
| title_sort | valbenazine for the treatment of adults with tardive dyskinesia |
| url | https://doi.org/10.52965/001c.24929 |
| work_keys_str_mv | AT harshitgupta valbenazineforthetreatmentofadultswithtardivedyskinesia AT alyceermoity valbenazineforthetreatmentofadultswithtardivedyskinesia AT allisonjumonville valbenazineforthetreatmentofadultswithtardivedyskinesia AT sarahkaufman valbenazineforthetreatmentofadultswithtardivedyskinesia AT ambernedinoff valbenazineforthetreatmentofadultswithtardivedyskinesia AT alandkaye valbenazineforthetreatmentofadultswithtardivedyskinesia |